Adoptive cell therapy using genetically modified antigen-presenting cells
|
|
- Alvin Terry
- 5 years ago
- Views:
Transcription
1 Adoptive cell therapy using genetically modified antigen-presenting cells Naoto Hirano Ontario Cancer Institute Princess Margaret Cancer Centre University of Toronto UofT-USP Oncology Conference November 15, 213
2 Adoptive transfer of antitumor T cells Establishes antitumor immunologic memory enabling life-long rejection of cancer cells.
3 Can we generate antitumor T cells in vitro which possesses an intrinsic capacity to persist as memory T cells in humans?
4 T cell grafts T cell clones Advantages Known Ag specificity and avidity (monoclonal). Disadvantages Higher chance of antigen escape. T cell lines Known Ag specificity with unknown avidity (polyclonal). Possibly not high avidity. Tumor-infiltrating lymphocytes Polyclonal Ag specificities; lower chance of antigen escape. Not available from all patients; specificities not completely defined. TCR-transduced T cells Off-the-shelf agent. Higher chance of Ag escape (monoclonal); possible TCR mispairing. CAR-transduced T cells Known Ag specificity and high avidity. Unexpected on/off target toxicites.
5 K562-based artificial antigen presenting cells (aapc) to generate antigen-specific CD8 + T cells IL-2 CD83 CD83L CD8 CD28/CTLA4 aapc-a2 aapc HLA-A2 TCR CD8 + T cell 1 ICAM-1 LFA-1 LFA-3 CD2 HLA-A2 CD8 CD83 ICAM-1 LFA IL K562: HLA class I/II -, CD8 ±, CD83 -, CD86 -, ICAM-1 +, LFA-3 +, PDL1/2 - (Hirano et al. Blood, 26)
6 Long-lived MART1 CTL generated with aapc MART1 specific CTL line Ficoll MART1 tetramer (Butler et al. Clin Cancer Res, 27)
7 Central memory ~ effector memory phenotype of antigen-specific T cells generated with aapc CD25 + CD27 + CD45 CD45 RA - CD28 +- CD62L +- CD69 + CCR7 RO + +-
8 Phase I study of the adoptive transfer of MART1/ Melan-A CTL for malignant melanoma (ClinicalTrials.gov, NCT512889) Eligibility HLA-A*2:1 Stage IV or unresectable stage III melanoma Absolute lymphocyte count >1,/µl Accessible tumor for excision/biopsy Exclusion Immunosuppressive therapy <3 days Active autoimmunity requiring immunosuppression
9 Generation of clinical grade CTL with aapc 33 aapc 33 Pulsed with MART1 peptide at 1 μg/ml Cytotoxicity A2 + PBMC from single pheresis Positively selected CD8 + T cells (CliniMacs) Multimer staining Interferon-γ ELISPOT Large scale stimulations every 7 days (3 weeks)
10 Generation of MART1 CTL using clinical grade aapc 33 MART1 Tetramer Stain MART1 Tetramer Positive Cells
11 Study timeline CTL Generation 1 CTL Generation 2 Leukapheresis 1 Infusion 1 Infusion 2 Leukapheresis 2 Leukapheresis 3 Day -21 Day Day 14 Day 35 Day 7 CTL generation Leukopheresis, select for CD8 + T cells, and 21 day culture with irradiated, MART1 peptide pulsed aapc 33 in IL-2 and IL-15 Two 35 days cycle 21 days of CTL culture 2nd infusion of CTL on day 35 Two dose levels Cohort one: 2 x 1 8 cells/m 2 Cohort two: 2 x 1 9 cells/m 2 No in vivo modulation No cytokine or vaccine therapy No lymphodepletion (Butler et al. Sci Transl Med, 211)
12 A Subject 7 Pre-infusion Post-infusion Multimer Adoptive transfer of MART1 CTL results in long-term increases in circulating MART1 T cells day day 35 day 7 day 126.2% 6.5% 6.4%.3%.19% CD8 B MART1 multimer + CTL (% CD8) Subject Subject 7 C MART1 multimer + CTL (% CD8) P =.1 P =.1 Day Infusions. Preinfusion day 14 day 49
13 Persistent MART1 T cells are phenotypically memory T cells Multimer CD45RA Subject 2 Pre-infusion.4% CD8 1.11% CD62L day 1 Post-infusion 54 day 12.8% Multimer CD45RA.2% Subject 7 5 Pre-infusion CD CD62L 5.58% day Post-infusion.3% 4 day day % Subject 8 Pre-infusion Post-infusion B Multimer CD45RA.3%.46% CD CD62L day 1 day 66.6% day 156.8% CD45RA - CD62L + expression on MART1 multimer + CTL (%) P =.2 Pre-infusion day 7
14 Persistent MART1 T cells are functionally memory T cells Subject 2 IFN- SFU/1 6 CD8 + T Cells 15 1 P =.1 5 Control MART1Control MART1 Pre-infusion day 56 IFN- SFU/1 6 CD8 + T Cells P =.2 A375 Malme-3M day 56 Subject 7 IFN- SFU/1 6 CD8 + T Cells P =.2 5 Control MART1Control MART1 Pre-infusion day 7 IFN- SFU/1 6 CD8 + T Cells P =.4 A375 Malme-3M day 7 Subject 8 IFN- SFU/1 6 CD8 + T Cells 5 25 P =.3 Control MART1Control MART1 IFN- SFU/1 6 CD8 + T Cells 5 25 P =.4 A375 Malme-3M Pre-infusion day 66 day 66
15 Infused MART1 CTL traffic to tumor sites Post-infusion day 5 Pre-infusion A CD CD8 1 5Vb14A 5Vb2B 5Vb2A 13.2% No V primer Foxp3 5Vb14A 5Vb2B 1 Expanded MART1 CTL 5Vb2A Multimer 12 Fresh TIL.54% No RNA 1 3 Multimer B No V primer CD4 Clonotypic CDR3 UbcH5B CD8 Graft 1 Graft 2
16 Complete resolution of metastatic melanoma following adoptive transfer A Pre-infusion Post-infusion day 74 day 14
17 No. Patient response to adoptive therapy Age/ sex Advanced cancer Day 7 status Time to next therapy 1 74M liver, adrenal, spleen, lung, skin Died on day M lung, skin 3 49F lung, adrenal Progressive disease Mixed response Day 13 Day M muscle, lung, mediastinum, cardiac Stable Day M multiple lymph nodes Partial response 54+ months (complete response without further therapy) 6 55M lung Stable Day F lung, skin Progressive disease Day M lung, mediastinal nodes Stable Day M lung, skin Progressive disease Day 146 As of November, 213
18 Basic Mechanisms of T Cell Stimulation and Inhibition Stimulation Inhibition
19 Anti-CTLA4 mab (Ipilimumab) Removes the brakes on the immune response. Induced 1-15% objective clinical response in advanced melanoma patients (Hodi et al. N Eng J Med, 211). Approved by FDA in 211 and Health Canada in 212.
20 A Anti-CTLA4 mab therapy promotes the expansion of infused CTL as memory T cells Pre-infusion Post-infusion day 74 day 167 day 224 day 537 CTLA-4 (+) Multimer CD45RA CD8 1.4% 1 5 CD62L 84.9%.11%.17% 7.8% V 14 69% B 25 P =.1 25 P <.1 IFN- SFU/1 5 PBMC Control MART1 Control MART1 IFN- SFU/1 5 PBMC A375 Malme-3M Pre-infusion day 537 day 537
21 Durable responses following CTLA4 blockade αctla-4 Subject 2: response 16 months αctla-4 Subject 3: response 61+ months
22 Patient Response to Anti-CTLA4 mab Therapy No. Age/ sex Time to next therapy Next therapy Outcome after next therapy Duration of response 1 74M -- Died without next therapy M Day 13 Ipilimumab (1 mg/kg) Partial response 16 months 3 49F Day 146 Ipilimumab (1 mg/kg) Partial response 61+ months 4 68M Day 14 BRAF inhibitor Stable 3 months 5 66M No further therapy No further therapy No further therapy 54+ months (complete response) 6 55M Day 287 High dose IL-2 Death due to sepsis F Day 335 Ipilimumab (3 mg/kg) Stable 6 months 8 8M Day 372 Ipilimumab (3 mg/kg) Stable 5 months 9 64M Day 146 Ipilimumab (1 mg/kg) + bevacizumab Partial response 43+ months As of November, 213
23 Other immunotherapeutics that can be combined with aapc-based adoptive T cell therapy TCR gene transfer A2/NY-ESO-1,A24/WT1 Checkpoint blockade CTLA-4, PD-1, PDL1 mab Cytokine administration IL-7, IL-15, IL-21 Vaccines DC, peptide, protein, DNA, RNA, adjuvant Non-myeloablative lymphodepletion Radiotherapy Small molecule inhibitors
24 Conclusions Artificial APC-based adoptive T cell therapy can establish antitumor immunologically memory in patients with advanced cancer without lymphodepletion or cytokine therapy. Checkpoint blockade can enhance pre-existing antitumor immunologically memory in patients with advanced cancer.
25 Effective combination immunotherapy with minimal toxicities in vivo T cell in vivo T cell immunity in vivo T cell immunity in vivo T cell immunity immunity Anti tumor Depletion Anti tumor Establishment Anti tumor Enhancement Anti tumor Lymphodepletion Adoptive transfer Vaccine Checkpoint blockade Cytokine
26 Acknowledgments Dana-Farber Cancer Institute Marcus Butler Philip Friedlander Makito Tanaka Stephen Hodi Osamu Imataki Linda Drury Alla Berezovskaya Lisa Brennan Mary Mooney Marisa Flavin Andrew Murray Donna Neuberg Genita Metzler Kristen Stevenson Matthew Milstein Lee Nadler Massachusetts General Hospital Donald Lawrence Martin Mihm Brigham and Women s Hospital Sara Russell Michael Jaklitsch Elsa Velasquez Ontario Cancer Institute/Princess Margaret Cancer Centre Munehide Nakatsugawa Shlomit Boguslavsky Yuki Yamashita Diana Gray Toshiki Ochi Valentin Sotov Kenji Chamoto Shinya Tanaka Marcus Butler Tingxi Guo
27 Acknowledgments Grant Support Immunotherapy Fund 1 S. Craig Lindner Fund for Cancer Research Rudolf E. Rupert Foundation for Cancer Research Cancer Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine Collaborative Friends of the Dana-Farber Cancer Institute Dunkin Donuts Rising Stars Program American Society of Hematology National Institute of Health/National Cancer Institute Ontario Regional Biotherapeutics Program (ORBiT) Ontario Institute for Cancer Research Campbell Family Institute for Breast Cancer Research Princess Margaret Cancer Foundation
Adoptive T Cell Therapy:
Adoptive T Cell Therapy: A Paradigm for Combination Strategies Cassian Yee MD Professor Melanoma Medical Oncology Immunology Director Solid Tumor Cell Therapy cyee@mdanderson.org skype name: tcelltherapy
More informationSupporting Information
Supporting Information Chapuis et al. 10.1073/pnas.1113748109 SI Methods Selection of Patients, Targets, Isolation, and Expansion of Melanoma- Specific CTL Clones. Patients were HLA-typed, and their tumors
More informationDEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationBET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models Yuki Kagoya,, Cheryl H. Arrowsmith, Naoto Hirano J Clin Invest. 2016;126(9):3479-3494. https://doi.org/10.1172/jci86437.
More informationCancer Immunotherapy. What is it? Immunotherapy Can Work! 4/15/09. Can the immune system be harnessed to fight cancer? T CD4 T CD28.
Cancer Immunotherapy CANCER BIOLOGY April 15, 2009 Can the immune system be harnessed to fight cancer? Can the immune system see cancer? What is the best way to turn on the immune system to fight cancer?
More informationVISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School
VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:
More informationAdoptive Cellular Therapy SITC Primer October 2012
Adoptive Cellular Therapy SITC Primer October 2012 Cassian Yee MD Member Fred Hutchinson Cancer Research Center Program in Immunology Clinical Research Division Professor University of Washington Division
More informationSupplemental materials
Supplemental materials 1 Supplemental Fig. 1 Immunogram This immunogram summarizes patient clinical data and immune parameters at corresponding time points for Patient IMF-32. The top panel illustrates
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationInterleukin-2 Single Agent and Combinations
Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers
More informationNIH Public Access Author Manuscript Science. Author manuscript; available in PMC 2008 March 12.
NIH Public Access Author Manuscript Published in final edited form as: Science. 2006 October 6; 314(5796): 126 129. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationAdvances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014
Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationImmunology and Immunotherapy 101 for the Non-Immunologist
Immunology and Immunotherapy 101 for the Non-Immunologist Stephen P. Schoenberger, Ph.D La Jolla Institute for Allergy and Immunology & UCSD Moores Cancer Center Disclosures Human Longevity Inc: Salary
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationEnhancing the Clinical Activity of HER2/neu Specific T Cells. William Gwin, MD Internal Medicine, Resident University of Washington
Enhancing the Clinical Activity of HER2/neu Specific T Cells William Gwin, MD Internal Medicine, Resident University of Washington Immunotherapy and Cancer Cancer vaccines were originally used in melanoma
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationExploiting tumour infiltrating lymphocytes (TILs) as a therapeutic strategy in epithelial ovarian cancer
Exploiting tumour infiltrating lymphocytes (TILs) as a therapeutic strategy in epithelial ovarian cancer G.L.Owens 1,2, V.Sheard 2, M.Price 1, D.E.Gilham 2, R.J.Edmondson 1 1 Gynaecological Oncology Research
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationRestoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma
Restoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma Goding SR et al. J Immunol 2013; 190:4899-4909 C. Nikolowsky Christian Doppler Laboratory for Cardiac and Thoracic
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationA Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients
A Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients Immunotherapy Biomarkers: Overcoming the Barriers NIH, Bethesda, April
More informationCellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU
Cellular Immune response Jianzhong Chen, Ph.D Institute of immunology, ZJU Concept of adaptive immune response T cell-mediated adaptive immune response I. Concept of immune response A collective and coordinated
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationFocus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human melanoma
Cancer Immun 1424-9634Academy of Cancer Immunology Cancer Immunity (2 April 2009) Vol. 9, p. 3 Copyright 2009 by Martin C. Mihm Jr. 090101 Review Focus on TILs: Prognostic significance of tumor infiltrating
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More informationCancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
More informationThe Good, the Bad and the Ugly: Clinical trials which assess vaccine characteristics. ISBT Meeting, San Francisco, CA November 4-8, 2004
The Good, the Bad and the Ugly: Clinical trials which assess vaccine characteristics ISBT Meeting, San Francisco, CA November 4-8, 2004 Ideal cancer vaccine trial 1. An informative immune assay 2. Ability
More informationMarshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011
Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Most common form of cancer in adults ages 25-29 3-5% of skin cancers but 65-75% of deaths Most common metastasis to small
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationExploring Therapeutic Combinations with anti-ctla-4 Antibody
Exploring Therapeutic Combinations with anti-ctla-4 Antibody Padmanee Sharma, MD, PhD Associate Professor GU Medical Oncology and Immunology M. D. Anderson Cancer Center isbtc Hot Topic Symposium October
More informationT Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Chandran SS, Somerville RPT, Yang JC, et al.
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationUnderstanding the T cell response to tumors using transnuclear mouse models
Understanding the T cell response to tumors using transnuclear mouse models Stephanie Dougan Dana-Farber Cancer Institute Boston, MA Presenter Disclosure Information Stephanie Dougan The following relationships
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More information- Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases.
암의면역치료 권병세 Immunotheraphy - Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases. - Applied for the treatment of cancer, autoimmune diseases, transplant rejection,
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationAdoptive Cell Therapy: Treating Cancer
Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationThe immune response against cancer
The immune response against cancer Maries van den Broek Institute of Experimental Immunology vandenbroek@immunology.uzh.ch The immune system Main cells of the immune system Dendritic cell Monocyte Macrophage
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationAdoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
Rohaan et al. Journal for ImmunoTherapy of Cancer (2018) 6:102 https://doi.org/10.1186/s40425-018-0391-1 REVIEW Adoptive transfer of tumor-infiltrating lymphocytes in : a viable treatment option Maartje
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationLecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells
1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:
More informationImmunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationAssessment of Efficacy and Immune Related RECIST criteria
Assessment of Efficacy and Immune Related RECIST criteria Dr Kenneth O Byrne Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Australia & Trinity College, Dublin, Ireland
More informationDiscover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15
Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15 Immunology in cancer The role of immunology in cancer Evolving knowledge of the immune system has provided a better understanding of
More informationImmunotherapies. Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting.
Immunotherapies Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting. INDEX Select a topic below for more information Principles of immunotherapy Classes
More informationEmerging Concepts of Cancer Immunotherapy
Emerging Concepts of Cancer Immunotherapy Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Immune Cell Infiltrate in Primary
More informationTumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma
Marmarelis et al. Journal for ImmunoTherapy of Cancer (2016) 4:26 DOI 10.1186/s40425-016-0129-x CASE REPORT Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More informationIs Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015
Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 J. J. Mulé Associate Center Director, Translational Research U.S. Senator Connie Mack & Family
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationNEON. Directing the Immune System THERAPEUTICS. January Neon Therapeutics
NEON THERAPEUTICS Directing the Immune System January 2019 1 Forward-Looking Statements and Intellectual Property Forward-Looking Statements This presentation may contain forward-looking statements. Forward-looking
More informationNew insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationCancer Vaccines. Patrick Ott. Melanoma Disease Center Center for Immuno-Oncology Dana Farber Cancer Institute Harvard Medical School
Cancer Vaccines Patrick Ott Melanoma Disease Center Center for Immuno-Oncology Dana Farber Cancer Institute Harvard Medical School Patrick A. Ott, MD, PhD The following relationships exist related to this
More informationIs Immune Therapy the Holy Grail in Metastatic Kidney Cancer?
Is Immune Therapy the Holy Grail in Metastatic Kidney Cancer? New Frontiers in Urologic Oncology 8-2016 Mayer Fishman, MD PhD Member, Moffitt Cancer Center Department of Genitourinary Oncology Professor,
More informationMucosal Immune System
Exam Format 100 points - 60 pts mandatory; 40 points where 4, 10 point questions will be chosen Some open-ended questions, some short answer. Kuby question Cytokines Terminology How do cytokines achieve
More informationMolecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationHuman leukocyte antigen (HLA) system
Is HLA a determinant of prognosis or therapeutic response to cytokines, IFN and anti-ctla4 blocking antibodies in melanoma? Helen Gogas, M.D. Ass. Professor in Medical Oncology 1st Department of Medicine,
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationEvaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab) and its Potential for Combination With Checkpoint Inhibitors
Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab) and its Potential for Combination With Checkpoint Inhibitors Tibor Keler, PhD Chief Scientific Officer Enhancing immunity with immune modulating
More informationLow Avidity CMV + T Cells accumulate in Old Humans
Supplementary Figure Legends Supplementary Figure 1. CD45RA expressing CMVpp65-specific T cell populations accumulate within HLA-A*0201 and HLA-B*0701 individuals Pooled data showing the size of the NLV/HLA-A*0201-specific
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationRaising the bar: optimizing combinations of targeted therapy and immunotherapy
Editorial Page 1 of 5 Raising the bar: optimizing combinations of targeted therapy and immunotherapy Alexandre Reuben 1, Jacob Austin-Breneman 1, Jennifer A. Wargo 1,2 *, Zachary A. Cooper 1,2 * 1 Department
More informationName of Policy: Yervoy (Ipilimumab)
Name of Policy: Yervoy (Ipilimumab) Policy #: 335 Latest Review Date: October 2013 Category: Pharmacology Policy Grade: A Background/Definitions: As a general rule, benefits are payable under Blue Cross
More information